Lucosky Brookman LLP Advises Tharimmune, Inc. on Closing of $1.74 Million Registered Direct Offering
Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company focused on advancing therapies in immunology and inflammation, has successfully closed its previously announced $1.74 million registered direct offering of securities to institutional investors under its effective shelf registration statement.
The offering consisted of 414,331 shares of common stock, 559,910 pre-funded warrants to purchase common stock, and 974,241 common warrants with an exercise price of $1.66 per share. Each unit, comprised of one share (or pre-funded warrant) and one common warrant, was priced at $1.786.
Lucosky Brookman LLP served as legal counsel to Tharimmune. President Street Global, LLC acted as the exclusive placement agent.
The Company plans to use the net proceeds for general corporate purposes, including advancing its clinical pipeline, funding research and development efforts, and supporting ongoing operations.
The transaction reflects Tharimmune’s ongoing commitment to developing novel therapies that address unmet needs in immunology and inflammation, and to building long-term value for shareholders.